General FAQs

Mereo BioPharma Group plc's American Depository Shares (ADSs) are listed on The Nasdaq Global Market.

The ticker symbol for Mereo BioPharma Group plc is NASDAQ: MREO. The CUSIP identifier for Mereo’s ADSs is 589492 107.

Our goal is to build a biopharmaceutical company developing and commercializing new therapies for oncology and rare diseases based on novel targets with strong scientific rationale.

Our mission is to provide new therapies to oncology patients and patients with rare diseases that have few, if any, other treatment options.

Our clinical-stage, oncology and rare disease assets originated in pharmaceutical or biotechnology companies where for strategic reasons they were not being progressed. With the streamlined efficiency of a small company and with our internal expertise and external resources we are able to rapidly progress the products into late stage development and the planned subsequent commercialization or partnership.

Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases.

Mereo will seek to selectively acquire oncology or clinical-stage rare disease product candidates with demonstrated clinically meaningful data from large pharmaceutical companies and to further develop these product candidates to subsequent key value inflection points or to commercialisation. By selectively acquiring and further developing promising product candidates, the Group and its stakeholders can jointly participate in the value realisation through any future sale, licensing or commercialisation of the product candidate.

Please refer to our SEC Filings page or the sec.gov EDGAR site.

Mereo’s registered office is:

Mereo BioPharma Group plc
Fourth Floor
One Cavendish Place
London
W1G 0QF
United Kingdom